Markus Tiemann

1.8k total citations
73 papers, 959 citations indexed

About

Markus Tiemann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Markus Tiemann has authored 73 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 17 papers in Immunology. Recurrent topics in Markus Tiemann's work include Lung Cancer Treatments and Mutations (25 papers), Mast cells and histamine (12 papers) and Cancer Genomics and Diagnostics (9 papers). Markus Tiemann is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Mast cells and histamine (12 papers) and Cancer Genomics and Diagnostics (9 papers). Markus Tiemann collaborates with scholars based in Germany, Russia and Switzerland. Markus Tiemann's co-authors include Igor Buchwalow, Dmitri Atiakshin, Vera Samoilova, Werner Boecker, Reza Parwaresch, Peter Bucsky, Martin Zimmermann, Georg Mann, R. Dopfer and Alfred Reiter and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Markus Tiemann

66 papers receiving 944 citations

Peers

Markus Tiemann
Sergei Syrbu United States
Ulrich Freudensprung Switzerland
Debra Saxe United States
Harumi Y. Mukai Japan
Rüediger Liersch Germany
Nadia Carboni Italy
Béatrice Marie France
Alessandra Bisagni Italy
Hyun Jung Jun South Korea
Juehua Gao United States
Sergei Syrbu United States
Markus Tiemann
Citations per year, relative to Markus Tiemann Markus Tiemann (= 1×) peers Sergei Syrbu

Countries citing papers authored by Markus Tiemann

Since Specialization
Citations

This map shows the geographic impact of Markus Tiemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Tiemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Tiemann more than expected).

Fields of papers citing papers by Markus Tiemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Tiemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Tiemann. The network helps show where Markus Tiemann may publish in the future.

Co-authorship network of co-authors of Markus Tiemann

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Tiemann. A scholar is included among the top collaborators of Markus Tiemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Tiemann. Markus Tiemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schmalzing, Marc, Oliver Sander, Reinhard Marks, et al.. (2024). Castleman’s disease in the rheumatological practice. Zeitschrift für Rheumatologie. 83(S3). 289–298.
2.
Falk, Markus, Stefanie Schmidt, Stefanie Schatz, et al.. (2023). Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Current Oncology. 30(2). 1692–1698. 6 indexed citations
3.
Костин, А. А., et al.. (2023). The Remodeling of Dermal Collagen Fibrous Structures in Mice under Zero Gravity: The Role of Mast Cells. International Journal of Molecular Sciences. 24(3). 1939–1939. 3 indexed citations
4.
Pirngruber, Judith, Eva‐Maria Willing, Markus Falk, et al.. (2023). The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. 30(10). 8805–8814. 2 indexed citations
5.
Михалева, Л.М., Nikolay K. Sadykhov, Dmitri Atiakshin, et al.. (2023). Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets. Biomedicines. 11(9). 2361–2361. 7 indexed citations
6.
Костин, А. А., et al.. (2023). Smooth Muscle Actin as a Criterion for Gravisensitivity of Stomach and Jejunum in Laboratory Rodents. International Journal of Molecular Sciences. 24(22). 16539–16539. 1 indexed citations
7.
Atiakshin, Dmitri, et al.. (2023). Mast Cell Tryptase and Carboxypeptidase A3 in the Formation of Ovarian Endometrioid Cysts. International Journal of Molecular Sciences. 24(7). 6498–6498. 5 indexed citations
8.
Rüschoff, Josef, Hans‐Ulrich Schildhaus, Jan H. Rüschoff, et al.. (2023). Testing for deficient mismatch repair and microsatellite instability. PubMed. 44(S2). 61–70. 10 indexed citations
9.
Atiakshin, Dmitri, et al.. (2023). Space-Flight- and Microgravity-Dependent Alteration of Mast Cell Population and Protease Expression in Digestive Organs of Mongolian Gerbils. International Journal of Molecular Sciences. 24(17). 13604–13604. 6 indexed citations
10.
Hoffmann, Christian, Marcus Hentrich, Markus Tiemann, et al.. (2022). Recent Advances in Castleman Disease. Oncology Research and Treatment. 45(11). 693–704. 15 indexed citations
11.
Atiakshin, Dmitri, et al.. (2021). Combined histochemical approach in assessing tryptase expression in the mast cell population. Acta Histochemica. 123(4). 151711–151711. 10 indexed citations
12.
Falk, Markus, Lukas C. Heukamp, Stefanie Schatz, et al.. (2021). Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. Pathology - Research and Practice. 227. 153651–153651. 2 indexed citations
13.
Atiakshin, Dmitri, Vera Samoilova, Igor Buchwalow, & Markus Tiemann. (2021). Expression of CD38 in Mast Cells: Cytological and Histotopographic Features. Cells. 10(10). 2511–2511. 4 indexed citations
14.
Atiakshin, Dmitri, Igor Buchwalow, & Markus Tiemann. (2019). Mast cell chymase: morphofunctional characteristics. Histochemistry and Cell Biology. 152(4). 253–269. 49 indexed citations
15.
Buchwalow, Igor, Vera Samoilova, Werner Boecker, & Markus Tiemann. (2018). Multiple immunolabeling with antibodies from the same host species in combination with tyramide signal amplification. Acta Histochemica. 120(5). 405–411. 32 indexed citations
16.
Falk, Martin, Stefanie Schatz, Markus Tiemann, et al.. (2018). P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts. Journal of Thoracic Oncology. 13(10). S494–S495. 7 indexed citations
17.
Prenzel, R., Kay Willborn, Cora Hallas, et al.. (2017). MA04.05 P53 Non-Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI. Journal of Thoracic Oncology. 12(1). S359–S360. 2 indexed citations
18.
Atiakshin, Dmitri, Vera Samoilova, Igor Buchwalow, Werner Boecker, & Markus Tiemann. (2017). Characterization of mast cell populations using different methods for their identification. Histochemistry and Cell Biology. 147(6). 683–694. 35 indexed citations
19.
Scheel, Andreas H., Manfred Dietel, Lukas C. Heukamp, et al.. (2016). Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie. Der Pathologe. 37. 17 indexed citations
20.
Griesinger, Frank, R. Prenzel, Cora Hallas, et al.. (2016). P53 non-disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI. Annals of Oncology. 27. vi426–vi426. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sergei Syrbu Breakdown of academic impact, for papers by Ulrich Freudensprung Breakdown of academic impact, for papers by Debra Saxe Breakdown of academic impact, for papers by Harumi Y. Mukai Breakdown of academic impact, for papers by Rüediger Liersch Breakdown of academic impact, for papers by Nadia Carboni Breakdown of academic impact, for papers by Béatrice Marie Breakdown of academic impact, for papers by Alessandra Bisagni Breakdown of academic impact, for papers by Hyun Jung Jun Breakdown of academic impact, for papers by Juehua Gao
Rankless by CCL
2026